More on 'Big Pharma Maintains Illusion of Innovation' (Response to Ken Johnson) [View article]
....in the United States I mean to add. I do not know about the EU or other countries. In the US - The things you mention do not happen anymore and haven't happened for a long, long time. Dr's can't even go to dinner with their wife at Burger King sponsored by pharma. In fact, the regulations have gotten so stiff, they are almost ridiculous.
More on 'Big Pharma Maintains Illusion of Innovation' (Response to Ken Johnson) [View article]
You obviously have very little knowledge of the current promotional and educational restrictions that the overwhelming majority of pharma and biotech manufacturers follow. Half of your argument is simply not valid anymore, and it hasn't been valid for years.
Would a Lilly/Imclone Deal Make Sense? [View article]
I think after the ridiculous handling of this situation by Carl Icahn, investors would be absolutely insane to let him take over any company in a hostile manner.
Listen to the turd boys. AMLN the turd is flushed down the toilet. LLY is out as a buyer, PFE is out as a buyer, no one's left to buy this stinker. See you at 10!
Buy biogen idec and Pfizer will lose every biogen idec employee (no biogen idec employee will work for a mammoth like pfizer), Rituxan (to Genentech), and possibly Tysabri (to Elan) as well. Your left with Avonex, with it's few short years left and an full pipeline that may or may not come to fruition. All that for at a price of at least 20 Billion? I think PFE will pass.
Lack of innovation among 'big pharma' is nothing new. Virtually all of the major blockbusters of today were discovered at the laboratories of small companies that were picked up on the cheap from these monstrous waste baskets. Who is to blame? Short term fund managers pressuring great small companies into deals. Who pays the price? Everyone.
Sort by:
Latest | Highest ratedMore on 'Big Pharma Maintains Illusion of Innovation' (Response to Ken Johnson) [View article]
More on 'Big Pharma Maintains Illusion of Innovation' (Response to Ken Johnson) [View article]
Amylin, Lilly: Another Case of a Panic Driven Sell-Off [View article]
Why I'm Buying Amylin Now [View article]
Amylin, Lilly: Another Case of a Panic Driven Sell-Off [View article]
Why I'm Buying Amylin Now [View article]
Amylin Shares Gain Ground on Outlook for Byetta [View article]
Would a Lilly/Imclone Deal Make Sense? [View article]
Why I'm Buying Amylin Now [View article]
Eli Lilly, ImClone: The Waiting Game Continues [View article]
Bristol-Meyers Squibb vs. Imclone: Icahn Stirs Up the Pot [View article]
If I recall, the open market placed the value of IMCL a lot less than 62.
I can't wait to hear who the mystery bidder is, and after DD they can't make a binding offer for whatever reason.
Amylin Shares Gain Ground on Outlook for Byetta [View article]
Why I'm Buying Amylin Now [View article]
A Bayer Buyout by Pfizer? [View article]
Big Pharma Pipeline: Why So Dry? [View article]